Marker Therapeutics
Marker Therapeutics develops advanced T cell-based immunotherapies for blood and solid tumor cancers, utilizing its proprietary Multi-Antigen Targeted (MultiTAA) technology.
Services
Marker Therapeutics specializes in developing next-generation T cell-based immunotherapies for patients suffering from blood and solid tumor cancers. Their therapies are uniquely designed to be administered in an outpatient setting, aligning with patients' needs for convenience and accessibility during treatment.
Technology
Marker Therapeutics utilizes a proprietary Multi-Antigen Targeted (MultiTAA) technology. This platform employs non-genetically modified cell therapy, selectively expanding tumor-specific T cells from a patient's blood. The MultiTAA-specific T cell therapies are engineered to target multiple tumor-associated antigens, thereby enhancing the tumor-killing capability and reducing the likelihood of tumor evasion.
Clinical Trials
Marker Therapeutics is currently enrolling patients in a multicenter randomized Phase 2 study focused on post-transplant acute myeloid leukemia (AML). The MultiTAA technology has been studied in hundreds of patients across various types of hematological cancers and solid tumors, demonstrating its broad application and potential efficacy.
Research and Development Team
Marker Therapeutics boasts a robust clinical-stage research and development team committed to pioneering innovative cancer immunotherapies. This team is integral to advancing the company’s mission of delivering effective, next-generation immunotherapy treatments to cancer patients.